journal
https://read.qxmd.com/read/38125609/surgical-options-for-aggressive-vertebral-hemangiomas%C3%AF-a-case-series-literature-review-and-treatment-recommendations
#21
JOURNAL ARTICLE
Mohamed Diaty Diarra, Zengjie Zhang, Zhan Wang, Eloy Yinwang, Hengyuan Li, Shengdong Wang, Peng Lin, Xin Huang, Zhaoming Ye
PURPOSE: We retrospectively study twenty-nine surgical cases of aggressive vertebral hemangiomas (AVHs) with neurological deficits and extradural compression to determine the optimal surgical treatment strategy for AVHs at a single institution. METHODS: Patients with AVHs with neurological deficits who underwent partial tumor resection plus decompression with or without vertebroplasty (VP), and radiotherapy between 2010 and 2021 were included in this study. Clinical characteristics, surgical outcomes, and follow-up data of the patients were reviewed retrospectively...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38075938/evaluation-of-pain-related-behaviors-and-disease-related-outcomes-in-an-immunocompetent-mouse-model-of-prostate-cancer-induced-bone-pain
#22
JOURNAL ARTICLE
Juan Miguel Jimenez-Andrade, Martha B Ramírez-Rosas, Sun Hee Park, Renee Parker, Matthew R Eber, Rebecca Cain, Mary Newland, Fang-Chi Hsu, Carol A Kittel, Thomas J Martin, Enriqueta Muñoz-Islas, Yusuke Shiozawa, Christopher M Peters
Cancer-induced bone pain (CIBP) is the most common and devastating symptom of bone metastatic cancer that substantially disrupts patients' quality of life. Currently, there are few effective analgesic treatments for CIBP other than opioids which come with severe side effects. In order to better understand the factors and mechanisms responsible for CIBP it is essential to have clinically relevant animal models that mirror pain-related symptoms and disease progression observed in patients with bone metastatic cancer...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38058514/tyrosine-kinase-inhibitors-in-osteosarcoma-adapting-treatment-strategiesa
#23
REVIEW
Ahmad Assi, Mohamad Farhat, Maria Catherine Rita Hachem, Ziad Zalaquett, Marven Aoun, Mohammad Daher, Amer Sebaaly, Hampig-Raphaël Kourie
Osteosarcoma (OS) is an aggressive primary bone malignancy that metastasizes rapidly. The standard of care has changed little over the previous four decades, and survival rates have plateaued. In this context, tyrosine kinase inhibitors (TKIs) emerge as potential treatments. A literature search was conducted to collect data related to receptor tyrosine kinase genetic alterations and expression in OS specimens. Gene amplification and protein expression of these receptors were linked to prognosis and tumor behavior...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38033413/intraosseous-conventional-central-chondrosarcoma-does-not-metastasise-irrespective-of-grade-in-pelvis-scapula-and-in-long-bone-locations
#24
JOURNAL ARTICLE
Minna K Laitinen, Joachim Thorkildsen, Guy Morris, Vineet Kurisunkal, Jonathan D Stevenson, Michael C Parry, Lee M Jeys
BACKGROUND: Histological grade has been regarded as the most important prognostic factor in conventional central chondrosarcoma. To evaluate whether the presence of an extraosseous tumour component is associated with a decreased metastasis-free survival or disease-specific survival and alternatively to develop a simple prognostic and clinical decision-making tool. MATERIAL AND METHODS: We searched two prospectively maintained international sarcoma centre databases for primary non metastatic central conventional chondrosarcomas of all grades in pelvis, scapula or long bone location, undergoing curative treatment, diagnosed between 2000 and 2020...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38021075/a-fusion-of-vgg-16-and-vit-models-for-improving-bone-tumor-classification-in-computed-tomography
#25
JOURNAL ARTICLE
Weimin Chen, Muhammad Ayoub, Mengyun Liao, Ruizheng Shi, Mu Zhang, Feng Su, Zhiguo Huang, Yuanzhe Li, Yi Wang, Kevin K L Wong
BACKGROUND AND OBJECTIVE: Bone tumors present significant challenges in orthopedic medicine due to variations in clinical treatment approaches for different tumor types, which includes benign, malignant, and intermediate cases. Convolutional Neural Networks (CNNs) have emerged as prominent models for tumor classification. However, their limited perception ability hinders the acquisition of global structural information, potentially affecting classification accuracy. To address this limitation, we propose an optimized deep learning algorithm for precise classification of diverse bone tumors...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38021074/targeting-transforming-growth-factor-beta-signaling-in-metastatic-osteosarcoma
#26
REVIEW
Rongrong Ge, Gavin M Huang
Osteosarcoma is a rare type of bone cancer, and half of the cases affect children and adolescents younger than 20 years of age. Despite intensive efforts to improve both chemotherapeutics and surgical management, the clinical outcome for metastatic osteosarcoma remains poor. Transforming growth factor β (TGF-β) is one of the most abundant growth factors in bones. The TGF-β signaling pathway has complex and contradictory roles in the pathogenesis of human cancers. TGF-β is primarily a tumor suppressor that inhibits proliferation and induces apoptosis of premalignant epithelial cells...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38021073/long-non-coding-rna-pvt1-pvt1-affects-the-expression-of-ccnd1-and-promotes-doxorubicin-resistance-in-osteosarcoma-cells
#27
JOURNAL ARTICLE
Zi Li, Jia-Ming Tian, Yi Chu, Hong-Yi Zhu, Jun-Jie Wang, Jun Huang
BACKGROUND: Acquired drug-resistance is the major risk factor for poor prognosis and short-term survival in patients with osteosarcoma (OS). Accumulating evidence has revealed that long noncoding RNAs (lncRNAs), including plasmacytoma variant translocation 1 (PVT1), play potential regulatory roles in the malignant development of OS. Considering the subcellular distribution of PVT1 as both nuclear and cytoplasmic lncRNA, a thorough exploration of its extensive mechanisms becomes essential...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/38021072/novel_circ_003686-regulates-the-osteogenic-differentiation-of-mscs-in-patients-with-myeloma-bone-disease-through-mir-142-5p-igf1-axis
#28
JOURNAL ARTICLE
Ling Qiu, Lei Ma, Dan Chen, Nan Zhang, Jiao Cai, Qian Zhang, Xiao Wang, Hai Yi, Hao Yao, Fang-Yi Fan
OBJECTIVES: Circ_003686 is a novel_circRNA with abnormally low expression found in the samples of multiple myeloma bone disease (MBD) patients. The current research intended to investigate the effects of novel_circ_003686 in osteogenesis-induced differentiation of bone marrow mesenchymal stem cells (BMSCs) in MBD. METHODS: BMSCs were extracted from MBD patients and normal participants, the pcDNA3.1 encoding the circ_003686 (ov-circ_003686), miR-142-5p-mimic/inhibitor and siRNA oligonucleotides targeting insulin like growth factor 1 (IGF1, si-IGF1) were applied to intervene circ_003686, miR-142-5p and IGF1 levels, respectively...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37868617/the-low-and-disproportionate-utilization-of-antiresorptive-therapy-in-patients-with-osseous-metastasis
#29
JOURNAL ARTICLE
Amil R Agarwal, Christa L LiBrizzi, Lauren Wessel, Savyasachi C Thakkar, Adam S Levin
INTRODUCTION: Antiresorptive therapies are commonly utilized to mitigate and prevent skeletal-related-events in patients with metastatic osseous disease. However, limited data exists on the incidence or factors associated with prescription of antiresorptives or their effects on the incidence of pathologic fractures in patients with osseous metastatic disease. The aims of this study were to determine 1) the proportion of patients with osseous metastasis who receive antiresorptive therapy and sustain a pathologic fracture within 2-years of a new diagnosis, 2) factors associated with sustaining a pathologic fracture, and 3) factors are associated with the likelihood of receiving antiresorptive therapy...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37868616/the-role-of-mitochondria-related-lncrnas-in-characterizing-the-immune-landscape-and-supervising-the-prognosis-of-osteosarcoma
#30
JOURNAL ARTICLE
Yiming Zhang, Nan Ru, Zhaowen Xue, Wenyi Gan, Ruilin Pan, Zelin Wu, Zihang Chen, Huajun Wang, Xiaofei Zheng
Mitochondrial damage is related to the functional properties of immune cells as well as to tumorigenesis and progression. Nevertheless, there is an absence concerning the systematic evaluation of mitochondria-associated lncRNAs (MALs) in the immune profile and tumor microenvironment of osteosarcoma patients. Based on transcriptomic and clinicopathological data from the TARGET database, MAL-related patterns were ascertained by consistent clustering, and gene set variation analysis of the different patterns was completed...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37842554/immune-checkpoint-inhibitors-in-bone-metastasis-clinical-challenges-toxicities-and-mechanisms
#31
REVIEW
Gwenyth J Joseph, Douglas B Johnson, Rachelle W Johnson
Immune checkpoint inhibitors (ICIs) have revolutionized the field of anti-cancer therapy over the last decade; they provide durable clinical responses against tumors by inhibiting immune checkpoint proteins that canonically regulate the T cell-mediated immune response. Despite their success in many primary tumors and soft tissue metastases, ICIs function poorly in patients with bone metastases, and these patients do not have the same survival benefit as patients with the same primary tumor type (e.g., non-small cell lung cancer [NSCLC], urothelial, renal cell carcinoma [RCC], etc...
December 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37771750/what-to-choose-in-bone-tumour-resections-patient-specific-instrumentation-versus-surgical-navigation-a-systematic-review
#32
REVIEW
Alessandro Bruschi, Davide Maria Donati, Claudia Di Bella
Patient specific instrumentation (PSI) and intraoperative surgical navigation (SN) can significantly help in achieving wide oncological margins while sparing bone stock in bone tumour resections. This is a systematic review aimed to compare the two techniques on oncological and functional results, preoperative time for surgical planning, surgical intraoperative time, intraoperative technical complications and learning curve. The protocol was registered in PROSPERO database (CRD42023422065). 1613 papers were identified and 81 matched criteria for PRISMA inclusion and eligibility...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37766930/femurtumornet-bone-tumor-classification-in-the-proximal-femur-using-densenet-model-based-on-radiographs
#33
JOURNAL ARTICLE
Canyu Pan, Luoyu Lian, Jieyun Chen, Risheng Huang
BACKGROUND & PURPOSE: For the best possible outcomes from therapy, proximal femur bone cancers must be accurately classified. This work creates an artificial intelligence (AI) model based on plain radiographs to categorize bone tumor in the proximal femur. MATERIALS AND METHODS: A tertiary referral center's standard anteroposterior hip radiographs were employed. A dataset 538 images of the femur, including malignant, benign, and tumor-free cases, was employed for training the AI model...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37736418/bone-tumor-examination-based-on-fcnn-4s-and-crf-fine-segmentation-fusion-algorithm
#34
JOURNAL ARTICLE
Shiqiang Wu, Xiaoming Bai, Liquan Cai, Liangming Wang, XiaoLu Zhang, Qingfeng Ke, Jianlong Huang
BACKGROUND AND OBJECTIVE: Bone tumor is a kind of harmful orthopedic disease, there are benign and malignant points. Aiming at the problem that the accuracy of the existing machine learning algorithm for bone tumor image segmentation is not high, a bone tumor image segmentation algorithm based on improved full convolutional neural network which consists fully convolutional neural network (FCNN-4s) and conditional random field (CRF). METHODOLOGY: The improved fully convolutional neural network (FCNN-4s) was used to perform coarse segmentation on preprocessed images...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37701913/a-randomized-trial-comparing-ly01011-biosimilar-candidate-with-the-reference-product-denosumab-xgeva%C3%A2-in-healthy-chinese-subjects
#35
JOURNAL ARTICLE
Yanhua Ding, Yusi Liu, Changlin Dou, Shuren Guo
BACKGROUND: Complications of bone metastases such as skeletal-related events lead to the impaired functional status and quality of life including death in patients with bone metastasis from solid tumors. Denosumab (XGEVA®) is indicated for the prevention of skeletal-related events in bone metastasis patients with solid tumors. The biosimilar product LY01011, a fully human anti-receptor activator of nuclear factor kappa-B ligand monoclonal antibody, was developed to be compared with the reference product denosumab...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37670740/contrast-enhanced-magnetic-resonance-image-segmentation-based-on-improved-u-net-and-inception-resnet-in-the-diagnosis-of-spinal-metastases
#36
JOURNAL ARTICLE
Hai Wang, Shaohua Xu, Kai-Bin Fang, Zhang-Sheng Dai, Guo-Zhen Wei, Lu-Feng Chen
OBJECTIVE: The objective of this study was to investigate the use of contrast-enhanced magnetic resonance imaging (CE-MRI) combined with radiomics and deep learning technology for the identification of spinal metastases and primary malignant spinal bone tumor. METHODS: The region growing algorithm was utilized to segment the lesions, and two parameters were defined based on the region of interest (ROI). Deep learning algorithms were employed: improved U-Net, which utilized CE-MRI parameter maps as input, and used 10 layers of CE images as input...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37664160/a-global-bibliometric-and-visualized-analysis-of-the-status-and-trends-of-bone-metastasis-in-breast-cancer-research-from-2002-to-2021
#37
JOURNAL ARTICLE
Li Li, Nengbin Wan, Ying He, Yi Zhang, Xiao He, Lingli Lu
UNLABELLED: Bone metastasis of breast cancer considerably reduces not only overall survival but also health-related quality of life due to pain, fatigue, and skeletal-related events. OBJECTIVE: This study aims to analyze the research hotspots and trends of global research on bone metastasis of breast cancer in the past 20 years to provide a reference for relevant personnel in this field to carry out academic research. METHODS: The literature related to bone metastasis of breast cancer from 2002 to 2021 was retrieved from the Web of Science...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37664159/dxa-assessment-and-fracture-prevention-in-hormone-positive-breast-cancer-patients-after-treatment-initiation-with-aromatase-inhibitors-a-registry-based-cohort-study
#38
JOURNAL ARTICLE
Vanessa Rouach, Yona Greenman, Gabriel Chodick, Inbal Goldshtein
BACKGROUND: Several guidelines have been proposed to prevent aromatase inhibitors induced bone loss (AIBL), but there is scarce data on their endorsement in clinical practice. AIM: To assess bone health evaluation and fracture prevention in postmenopausal women with estrogen receptor (ER)-positive breast cancer after aromatase inhibitors (AI) initiation. METHODS: An historical cohort analysis based on data from the cancer and osteoporosis Maccabi Health Services (MHS) registries from Jan 1st 2009 to Dec 31st 2020...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37635708/implant-failure-and-revision-strategies-after-total-spondylectomy-for-spinal-tumors
#39
JOURNAL ARTICLE
Xianglin Hu, Sean M Barber, Yingzheng Ji, Hongwei Kou, Weiluo Cai, Mo Cheng, Hongjian Liu, Wending Huang, Wangjun Yan
BACKGROUND: Although there have been several risk factors reported for implant failure (IF), little consensus exists. Potential applicable measures to protect patients from IF are relatively few. This study aimed to discover new risk factors for IF and explore potential protective measures from IF after total spondylectomy for spinal tumors. METHODS: A total of 145 patients undergoing total spondylectomy for thoracic and lumbar spinal tumors between 2010 and 2021 were included from three tertiary university hospitals...
October 2023: Journal of Bone Oncology
https://read.qxmd.com/read/37589036/optimal-timing-for-local-ablative-treatment-of-bone-oligometastases-in-non-small-cell-lung-cancer
#40
REVIEW
Jayoung Lee, Jung A Kim, Tai Joon An, Hyochun Lee, Eun Ji Han, Young Jo Sa, Hyo Rim Kim, Chan Kwon Park, Tae-Jung Kim, Jeong Uk Lim
Oligometastases is a term commonly used to describe a disease state characterized by a limited number of distant metastases, and represents a transient phase between localized and widespread systemic diseases. This subgroup of stage IV cancer has increased in clinical importance due to the possibility of curative rather than palliative treatment. Among advanced lung cancer patients, 30-40% show bone metastases, and can show complications such as pathological fractures. Many prospective studies have shown efficacy of localized treatment in oligometastatic non-small cell lung cancer (NSCLC) in improving progression-free survival and overall survival...
October 2023: Journal of Bone Oncology
journal
journal
49840
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.